Maria Cristina Manara

List of Publications by Year
in descending order

103 papers	4,923 citations	76196 40 h-index	98622 67 g-index
103 all docs	103 docs citations	103 times ranked	5006 citing authors

#	Article	IF	Citations
1	Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome. New England Journal of Medicine, 1995, 333, 1380-1385.	13.9	372
2	Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors. Cancer Research, 2005, 65, 3868-3876.	0.4	272
3	CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. Journal of Clinical Investigation, 2010, 120, 668-680.	3.9	150
4	NVP-BEZ235 as a New Therapeutic Option for Sarcomas. Clinical Cancer Research, 2010, 16, 530-540.	3.2	142
5	miRâ€34a predicts survival of Ewing's sarcoma patients and directly influences cell chemoâ€sensitivity and malignancy. Journal of Pathology, 2012, 226, 796-805.	2.1	128
6	Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor-Specific Inhibitor in Ewing's Sarcoma. Clinical Cancer Research, 2007, 13, 1322-1330.	3.2	126
7	Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewingâ€™s sarcoma. European Journal of Cancer, 2005, 41, 1349-1361.	1.3	123
8	Overcoming Resistance to Conventional Drugs in Ewing Sarcoma and Identification of Molecular Predictors of Outcome. Journal of Clinical Oncology, 2009, 27, 2209-2216.	0.8	121
9	Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene, 2011, 30, 2730-2740.	2.6	119
10	Molecular mechanisms of CD99-induced caspase-independent cell death and cellâ€“cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene, 2004, 23, 5664-5674.	2.6	108
11	miRNA expression profile in human osteosarcoma: Role of miR-1 and miR-133b in proliferation and cell cycle control. International Journal of Oncology, 2013, 42, 667-675.	1.4	106
12	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Therapy, 2002, 9, 296-307.	2.2	101
13	CD99 at the crossroads of physiology and pathology. Journal of Cell Communication and Signaling, 2018, 12, 55-68.	1.8	101
14	The Expression of ccn3(nov) Gene in Musculoskeletal Tumors. American Journal of Pathology, 2002, 160, 849-859.	1.9	99
15	Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. International Journal of Cancer, 2002, 101, 11-16.	2.3	96
16	Value of P-Glycoprotein and Clinicopathologic Factors as the Basis for New Treatment Strategies in High-Grade Osteosarcoma of the Extremities. Journal of Clinical Oncology, 2003, 21, 536-542.	0.8	95
17	Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor. Human Pathology, 1996, 27, 408-416.	1.1	94
18	Clinical relevance of Ki-67 expression in bone tumors. Cancer, 1995, 75, 806-814.	2.0	90

#	Article	IF	Citations
19	In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene, 2005, 24, 4349-4361.	2.6	90
20	Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Annals of Oncology, 2004, 15, 151-160.	0.6	83
21	Caveolin-1 Reduces Osteosarcoma Metastases by Inhibiting c-Src Activity and Met Signaling. Cancer Research, 2007, 67, 7675-7685.	0.4	81
22	Redundancy of autocrine loops in human osteosarcoma cells. , 1999, 80, 581-588.		78
23	Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB Journal, 2003, 17, 1162-1164.	0.2	72
24	c-kit Receptor Expression in Ewingâ€™s Sarcoma: Lack of Prognostic Value but Therapeutic Targeting Opportunities in Appropriate Conditions. Journal of Clinical Oncology, 2003, 21, 1952-1960.	0.8	71
25	Insulinâ€like growth factor 1 receptor expression in wildâ€type GISTs: A potential novel therapeutic target. International Journal of Cancer, 2009, 125, 2991-2994.	2.3	70
26	Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewingâ€™s sarcoma. European Journal of Cancer, 2006, 42, 91-96.	1.3	69
27	Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects. International Journal of Cancer, 2004, 108, 358-366.	2.3	61
28	CD99 Acts as an Oncosuppressor in Osteosarcoma. Molecular Biology of the Cell, 2006, 17, 1910-1921.	0.9	60
29	CD99: A Cell Surface Protein with an Oncojanus Role in Tumors. Genes, 2018, 9, 159.	1.0	60
30	CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. Oncogene, 2007, 26, 6604-6618.	2.6	59
31	Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2017, 23, 5149-5161.	3.2	59
32	Impact of IGF-I/IGF-IR Circuit on the Angiogenetic Properties of Ewingâ€™s Sarcoma Cells. Hormone and Metabolic Research, 2003, 35, 675-684.	0.7	53
33	Identification of Common and Distinctive Mechanisms of Resistance to Different Anti-IGF-IR Agents in Ewing's Sarcoma. Molecular Endocrinology, 2012, 26, 1603-1616.	3.7	53
34	Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. Scientific Reports, 2019, 9, 12174.	1.6	52
35	CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-ÎºB signaling. Oncogene, 2016, 35, 3944-3954.	2.6	51
36	Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. International Journal of Cancer, 2006, 119, 1039-1046.	2.3	49

#	Article	IF	Citations
37	Expression of insulin-like growth factor system components in Ewingâ€™s sarcoma and their association with survival. European Journal of Cancer, 2011, 47, 1258-1266.	1.3	49
38	Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. Annals of Oncology, 2008, 19, 1500-1508.	0.6	48
39	Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Letters, 2007, 250, 194-205.	3.2	43
40	Metformin as an Adjuvant Drug against Pediatric Sarcomas: Hypoxia Limits Therapeutic Effects of the Drug. PLoS ONE, 2013, 8, e83832.	1.1	43
41	CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin. Clinical Cancer Research, 2015, 21, 146-156.	3.2	42
42	CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. Oncogene, 2014, 33, 1912-1921.	2.6	41
43	CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling. Oncotarget, 2016, 7, 79925-79942.	0.8	40
44	Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents. Clinical Cancer Research, 2015, 21, 1373-1382.	3.2	39
45	Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clinical Cancer Research, 2002, 8, 3893-903.	3.2	39
46	Analysis of P-glycoprotein expression in osteosarcoma. European Journal of Cancer, 1995, 31, 1998-2002.	1.3	38
47	Characterization of Human Mesenchymal Stem Cells from Ewing Sarcoma Patients. Pathogenetic Implications. PLoS ONE, 2014, 9, e85814.	1.1	38
48	CD99 Drives Terminal Differentiation of Osteosarcoma Cells by Acting as a Spatial Regulator of ERK 1/2. Journal of Bone and Mineral Research, 2014, 29, 1295-1309.	3.1	37
49	Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Influences Sensitivity to Anti-IGF System Agents Through the Translational Regulation of IGF1R. Frontiers in Endocrinology, 2018, 9, 178.	1.5	37
50	Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. European Journal of Cell Biology, 2003, 82, 483-493.	1.6	36
51	ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity. Journal of Experimental and Clinical Cancer Research, 2019, 38, 503.	3.5	36
52	The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene, 1999, 18, 739-746.	2.6	35
53	Reversal of malignant phenotype in human osteosarcoma cells transduced with the alkaline phosphatase gene. Bone, 2000, 26, 215-220.	1.4	35
54	Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression. Annals of Oncology, 2014, 25, 2080-2086.	0.6	35

#	Article	IF	Citations
55	Identification of candidate genes involved in the reversal of malignant phenotype of osteosarcoma cells transfected with the liver/bone/kidney alkaline phosphatase gene. Bone, 2004, 34, 672-679.	1.4	33
56	A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy. Molecular Cancer Therapeutics, 2018, 17, 1881-1892.	1.9	33
57	Biological indicators of prognosis in Ewing's sarcoma: An emerging role for lectin galactosideâ€binding soluble 3 binding protein (LGALS3BP). International Journal of Cancer, 2010, 126, 41-52.	2.3	31
58	Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells. Clinical Epigenetics, 2019, 11, 68.	1.8	30
59	RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells. British Journal of Cancer, 2006, 94, 1300-1310.	2.9	26
60	Domain-specific CCN3 antibodies as unique tools for structural and functional studies. Journal of Cell Communication and Signaling, 2007, 1, 91-102.	1.8	24
61	Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99. Oncogene, 2018, 37, 2181-2196.	2.6	24
62	Murine model for skeletal metastases of Ewing's sarcoma. Journal of Orthopaedic Research, 2000, 18, 959-966.	1.2	22
63	Identification of EWS/FLI-1 transcripts in giant-cell tumor of bone. International Journal of Cancer, 2000, 87, 328-335.	2.3	21
64	Xg Expression in Ewing's Sarcoma Is of Prognostic Value and Contributes to Tumor Invasiveness. Cancer Research, 2010, 70, 3730-3738.	0.4	21
65	Targeting Glutathione-S Transferase Enzymes in Musculoskeletal Sarcomas: A Promising Therapeutic Strategy. Analytical Cellular Pathology, 2011, 34, 131-145.	0.7	20
66	Oxidative Stress in Autistic Children Alters Erythrocyte Shape in the Absence of Quantitative Protein Alterations and of Loss of Membrane Phospholipid Asymmetry. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-11.	1.9	20
67	May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. International Journal of Oncology, 2006, 29, 1459-68.	1.4	20
68	Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma. Cells, 2021, 10, 416.	1.8	19
69	Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells. Growth Factors, 2014, 32, 41-52.	0.5	18
70	ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents. Oncotarget, 2015, 6, 16611-16622.	0.8	18
71	Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewingâ€™s Sarcoma Tumor Cells. Current Pharmaceutical Biotechnology, 2013, 14, 449-463.	0.9	18
72	Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. Analytical Cellular Pathology, 2011, 34, 131-45.	0.7	17

#	Article	IF	Citations
73	Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma. Cancer Research, 2022, 82, 708-720.	0.4	16
74	Pre-Treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin. International Journal of Cancer, 1994, 58, 95-101.	2.3	15
75	Prognostic Significance of Nuclear Accumulation of c-myc and mdm2 Proteins in Synovial Sarcoma of the Extremities. Oncology, 2000, 58, 253-260.	0.9	15
76	Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma. Journal of Cancer Research and Clinical Oncology, 1992, 119, 121-126.	1.2	13
77	An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. BMC Cancer, 2014, 14, 137.	1.1	13
78	Targeting ROCK2 rather than ROCK1 inhibits Ewing sarcoma malignancy. Oncology Reports, 2017, 37, 1387-1393.	1.2	12
79	Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Modulates Aggressiveness of Ewing Sarcoma by Regulating the CD164-CXCR4 Axis. Frontiers in Oncology, 2020, 10, 994.	1.3	12
80	Simultaneous Paired Analysis of Numerical Chromosomal Aberrations and DNA Content in Osteosarcoma. Modern Pathology, 2001, 14, 710-716.	2.9	11
81	Ewing Sarcoma PDX Models. Methods in Molecular Biology, 2021, 2226, 223-242.	0.4	11
82	4-Demethoxy-3â€²-deamino-3â€²-aziridinyl-4â€²-methylsulphonyl-daunorubicin (PNU-159548): A promising new candidate for chemotherapeutic treatment of osteosarcoma patients. European Journal of Cancer, 2005, 41, 2184-2195.	1.3	9
83	Impact of ABC Transporters in Osteosarcoma and Ewingâ€™s Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?. Cells, 2021, 10, 2461.	1.8	9
84	Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma. Journal of Cell Communication and Signaling, 2020, 14, 335-347.	1.8	8
85	Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis. Current Pharmaceutical Design, 2013, 19, 5344-5361.	0.9	8
86	Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma. Cell Death and Disease, 2022, 13, 346.	2.7	7
87	Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities. Cytotechnology, 1996, 19, 253-256.	0.7	6
88	Process development of a human recombinant diabody expressed in E. coli: engagement of CD99-induced apoptosis for target therapy in Ewingâ€™s sarcoma. Applied Microbiology and Biotechnology, 2016, 100, 3949-3963.	1.7	6
89	Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study. Cancers, 2022, 14, 2863.	1.7	6
90	Novel Targeting of DNA Methyltransferase Activity Inhibits Ewing Sarcoma Cell Proliferation and Enhances Tumor Cell Sensitivity to DNA Damaging Drugs by Activating the DNA Damage Response. Frontiers in Endocrinology, 2022, 13, .	1.5	4

#	Article	IF	Citations
91	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. , 0, .		1
92	Abstract 1933: Discovery of first-in-class small molecule CD99 inhibitors for targeted therapy of Ewing sarcoma. , 2017, , .		1
93	Abstract 3406: Prognostic relevance of Wnt-beta catenin signaling in Ewing's sarcoma. , 2010, , .		0
94	Abstract 728: Molecular mechanisms of resistance to anti-IGF-1R therapies in Ewing's sarcoma. , 2011, , .		0
95	Abstract 167: Identification of miR-34a as a prognostic biomarker of Ewing sarcoma family of tumors. , 2011, , .		0
96	Abstract 5340: Regulation of osteoblast differentiation: The pivotal role of CD99 molecule. , 2011, , .		0
97	Abstract 4140: MicroRNA expression in Osteosarcoma: potential role of miR-1 and miR-133b. , 2012, , .		0
98	Abstract 4325: CD99 suppresses osteosarcoma cell migration by favouring the oncosoppressor N-cadherin/beta-catenin signalling pathway in contrast to ezrin.. , 2012, , .		0
99	Abstract 2946: Effects of two novel quinoline-based non-nucleoside DNA methyltransferase inhibitors against bone sarcomas. , 2015, , .		0
100	Does <i>MGMT</i> (O6-methylguanineâ€"DNA methyltransferase) have a role in metastatic Ewing sarcoma (ES) patients (pts) undergoing temozolomide (TMZ) and irinotecan (IRI)?. Journal of Clinical Oncology, 2017, 35, 11030-11030.	0.8	0
101	Abstract 2079: Collection of patient-derived xenografts (PDX) to study the biology and therapy of bone sarcomas. , 2018, , .		0
102	Abstract A06: Inhibition of CD99 activity by clofarabine as a novel therapeutic for Ewing sarcoma involves a novel molecular mechanism that is different than cytarabine. , 2018, , .		0
103	Abstract 3672: Insulin-like growth factor 2 (IGF-2) mRNA binding protein 3-mediated regulation of CD164-CXCR4 axis impacts aggressiveness of Ewing sarcoma. , 2019, , .		0